AbbVie Inc (ABBV)vsVarex Imaging Corp (VREX)
ABBV
AbbVie Inc
$243.87
-0.95%
HEALTHCARE · Cap: $430.82B
VREX
Varex Imaging Corp
$12.25
-1.13%
HEALTHCARE · Cap: $466.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7409% more annual revenue ($64.39B vs $857.50M). ABBV leads profitability with a 9.8% profit margin vs -9.6%. ABBV appears more attractively valued with a PEG of 0.41. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
VREX
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$243.87
$92.97 premium
Margin of Safety
+14.6%
Fair Value
$15.93
Current Price
$12.25
$3.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 453.4% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
1.5% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : VREX
The strongest argument for VREX centers on Price/Book, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : VREX
The primary concerns for VREX are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while VREX is a turnaround play — different risk/reward profiles.
VREX carries more volatility with a beta of 0.90 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 52/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Varex Imaging Corp
HEALTHCARE · MEDICAL DEVICES · USA
Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?